Header

Pediatric Solid Tumors Clinical Trials

Category:Pediatric
Status:Active

Displaying all 30 Trial

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ ...

Diagnosis: Pediatric Solid Tumors, Other Cancers

Phase: 3

Protocol Number: 16-701

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.

Diagnosis: Pediatric Solid Tumors

Phase: 3

Protocol Number: 18-731

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID administered orally in continuous 28 day cycles. Screening of subjects to determine eligibility for...

Diagnosis: Sarcoma, Pediatric Solid Tumors

Phase: 2

Protocol Number: 15-512

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas ...

Diagnosis: Pediatric Solid Tumors

Phase: 1 / 2

Protocol Number: 16-722

Study of Selinexor in Pediatric Solid Tumors

The investigators will conduct a phase 1 trial of Selinexor in children with recurrent or refractory solid tumors, including CNS tumors using the Rolling Six design. The aims of the trial will be t...

Diagnosis: Pediatric Solid Tumors

Phase: 1

Protocol Number: 15-718

Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors

This is a 4-part, open-label, Phase 1/1b, dose escalation study in pediatric patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; and 4) non-neuroblastoma, extra...

Diagnosis: Pediatric Solid Tumors

Phase: 1

Protocol Number: 16-045

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.

Diagnosis: Pediatric Solid Tumors, Pediatric Lymphoma

Phase: 1

Protocol Number: 16-371

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood...

Diagnosis: Pediatric Solid Tumors

Phase: N/A

Protocol Number:

The iCat2, GAIN Consortium Study

This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling. The tumor profili...

Diagnosis: Pediatric Solid Tumors

Phase: N/A

Protocol Number: 15-169

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

This is a 3-part (Part A, Part B, Part C), Phase I/IIa, multi-center, open label, study in pediatric subjects with refractory or recurrent tumors. Part A is a repeat dose, dose escalation monothera...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 15-079

Phase I Trial of Afatinib in Pediatric Tumours

Open-label, dose escalation, monotherapy, basket trial with biomarker specific MTD expansion cohort The trial will consist of 2 parts: 1. Dose finding part to determine the MTD 2. Biomarker specifi...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 15-315

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)

This is a 2-part study of pembrolizumab (MK-3475) in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed or refractory s...

Diagnosis: Pediatric Solid Tumors, Pediatric Lymphoma

Phase:

Protocol Number: 16-235

WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

This phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have n...

Diagnosis: Pediatric Solid Tumors, Pediatric Brain Tumor

Phase:

Protocol Number: 16-447

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 17-700

Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients

This is an open label expanded access protocol for the treatment of up to approximately 40 adult or pediatric (defined as age <18 years) patients with tumors harboring either a chromosomal trans...

Diagnosis: Pediatric Solid Tumors, Pediatric Leukemia

Phase:

Protocol Number: 16-555

Identification of Biomarkers for Patients With Vascular Anomalies

The study will use participants tissue previously collected and stored in a tissue bank maintained by the Department of Hematology/Oncology as well as tissue banked in the future from participants ...

Diagnosis: Pediatric Solid Tumors, Pediatric Sarcoma

Phase:

Protocol Number:

Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

This phase I trial studies the side effects and best dose of nanoparticle albumin-bound rapamycin when given together with temozolomide and irinotecan hydrochloride in treating pediatric patients w...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 17-728

Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

This phase I trial studies the side effects and best dose of pevonedistat when giving together with irinotecan hydrochloride and temozolomide in treating patients with solid tumors or lymphoma that...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 17-746

Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations

This phase II trial studies how well PI3K/mTOR inhibitor LY3023414 works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that ...

Diagnosis: Pediatric Solid Tumors, Pediatric Oncology

Phase:

Protocol Number: 17-742

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD...

Diagnosis: Pediatric Leukemia, Pediatric Solid Tumors, Pediatric Lymphoma

Phase:

Protocol Number: 17-617

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib ...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 17-513

VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

This phase I/II trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 (VX15/2503) and to see how well it works in treating younger patients with solid tumors tha...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 18-704

Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers

This is a Phase 1/2, multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients age ≥ 1 month and older with NTRK fusion cancers tr...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 17-481

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to st...

Diagnosis: Pediatric Solid Tumors, Pediatric Lymphoma

Phase:

Protocol Number: 18-141

Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention

The goal of this new intervention is to make it easier for families to meet their basic household needs during childhood cancer treatment. The investigators want to learn how to best use PediCARE t...

Diagnosis: Pediatric Brain Tumor, Pediatric Solid Tumors, Pediatric Hematology/Blood Related

Phase:

Protocol Number: 18-294

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia. The drugs involved in this study are...

Diagnosis: Pediatric Leukemia, Pediatric Brain Tumor, Pediatric Lymphoma, Pediatric Solid Tumors

Phase:

Protocol Number: 18-284

Axitinib and Nivolumab in Treating Participants With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma

This phase II trial studies how well axitinib and nivolumab works in treating participants with TFE/translocation renal cell carcinoma that cannot be removed by surgery or has spread to other place...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 19-708

Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma

This is a multicenter, 1:1 randomized Phase III study of intradermal autologous Vigil immunotherapy (1.0 x 10e6 cells/injection; minimum of 4 to a maximum of 12 administrations) in combination with...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 18-521

A Study of Therapeutic Iobenguane (131-I) for Relapsed, High-Risk Neuroblastoma Subjects

The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in patients with neuroblastoma, who relapsed.

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 18-595

Durvalumab and Tremelimumab for Pediatric Malignancies

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in ...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 19-116

'